Bone marrow-derived stem cells offer blood transplant patients better quality of life

August 16, 2016, Fred Hutchinson Cancer Research Center

A large, nationwide study published in the journal JAMA Oncology found that people who received transplants of cells collected from a donor's bone marrow the original source for blood stem cell transplants, developed decades ago had better self-reported psychological well-being, experienced fewer symptoms of a common post-transplant side effect called graft-vs.-host disease and were more likely to be back at work five years after transplantation than those whose transplanted cells were taken from the donor's bloodstream.

"We're hoping that once we provide information about long-term quality of life and recovery, patients and their doctors can take this into account when they're planning their transplants," said lead author Dr. Stephanie Lee of Fred Hutchinson Cancer Research Center. She noted that the results would only be applicable to transplant patients who are similar to those enrolled in the trial.

The study also showed that there was no difference in overall survival, treatment-related death or relapse between the two groups of study participants. Lee said that this result would reassure the many patients for whom survival is the top concern.

"There are many ways to do a transplant. Choosing a source of is just one decision. But anything that improves the success of transplant can help future patients," she said.

The study included 551 people between age 16 and 66 with leukemia or certain other blood malignancies who needed to receive a transplant of from an unrelated donor. The patients were randomly assigned to one of the two types of transplants. From 6 months to five years after the transplant, study researchers called the participants periodically to assess how they were doing.

The researchers found that people whose transplanted cells were derived from their donor's bone marrow were more likely to report better others than those assigned to receive the stem cells from circulating, or peripheral, blood. They were also much more likely to have returned to at least part-time work than their counterparts in the group.

"Results of this study set bone marrow as the standard source of stem cells for transplantation from unrelated donors" said Dr. Claudio Anasetti, senior author of the study and chair of the Department of Blood and Marrow Transplantation at Moffitt Cancer Center.

The researchers suspected, but could not confirm, that these patients had better emotional well-being because they also experienced fewer self-reported symptoms of chronic , or GVHD, and had fewer side effects from GVHD treatment. Chronic GVHD is a common transplant complication in which transplanted immune cells turn against the patient's healthy cells, causing symptoms such as a debilitating thickening of the skin and permanent loss of lung function.

This condition is a major focus of Lee's research as research director of Fred Hutch's Long-Term Follow-Up Program, which provides lifelong monitoring and care of transplant patients, and as leader of a national research consortium on chronic GVHD.

The study led by Lee is the latest example of the decades of research by many scientists that has continued to improve transplantation and related forms of blood stem cell transplantation by boosting the therapy's success rates and decreasing toxicity.

"When both your disease and the recommended treatment are life-threatening, I don't think people are necessarily asking 'which treatment is going to give me better quality of life years from now?'" Lee said. "Yet, if you're going to make it through, as many do, you want to do it with good quality of life. That's the whole point of having the . It's not just to cure your disease but also to try to get back to as normal of lifestyle as you can."

Explore further: Researchers develop new strategy to limit side effects of stem cell transplants

Related Stories

Researchers develop new strategy to limit side effects of stem cell transplants

August 15, 2016
Scientists in Germany have developed a new approach that may prevent leukemia and lymphoma patients from developing graft-versus-host disease (GvHD) after therapeutic bone marrow transplants. The researchers describe the ...

No survival advantage with peripheral blood stem cells versus bone marrow

October 19, 2012
(Medical Xpress)—Claudio Anasetti, M.D., chair of the Department of Blood & Marrow Transplant at Moffitt Cancer Center, and colleagues from 47 research sites in the Blood and Marrow Transplant Clinical Trials Network conducted ...

Cord blood outperforms matched, unrelated donor in bone marrow transplant

July 26, 2016
A University of Colorado Cancer Center study compared outcomes of leukemia patients receiving bone marrow transplants from 2009-2014, finding that three years post transplant, the incidence of severe chronic graft-versus-host ...

Less toxic bone marrow transplants on horizon

August 10, 2016
Bone marrow transplants that do not require dangerous and often toxic chemotherapy could soon be possible, US researchers said Wednesday after seeing initial success with experiments on mice.

Leading bone marrow transplant expert recommends significant change to current practice

October 17, 2012
One of the world's leading bone marrow transplant experts is recommending a significant change to current transplant practice for patients who need marrow or adult stem cells from an unrelated donor to treat hematologic malignancies. ...

Groundbreaking study that may change transplant practices

November 20, 2012
Researchers from John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's 50 best cancer centers, played an important role in a study published in the New England Journal of Medicine on October ...

Recommended for you

A small, daily dose of Viagra may reduce colorectal cancer risk

March 19, 2018
A small, daily dose of Viagra significantly reduces colorectal cancer risk in an animal model that is genetically predetermined to have the third leading cause of cancer death, scientists report.

Cancer comes back all jacked up on stem cells

March 19, 2018
After a biopsy or surgery, doctors often get a molecular snapshot of a patient's tumor. This snapshot is important - knowing the genetics that cause a cancer can help match a patient with a genetically-targeted treatment. ...

Researchers create a drug to extend the lives of men with prostate cancer

March 16, 2018
Fifteen years ago, Michael Jung was already an eminent scientist when his wife asked him a question that would change his career, and extend the lives of many men with a particularly lethal form of prostate cancer.

Machine-learning algorithm used to identify specific types of brain tumors

March 15, 2018
An international team of researchers has used methylation fingerprinting data as input to a machine-learning algorithm to identify different types of brain tumors. In their paper published in the journal Nature, the team ...

Higher doses of radiation don't improve survival in prostate cancer

March 15, 2018
A new study shows that higher doses of radiation do not improve survival for many patients with prostate cancer, compared with the standard radiation treatment. The analysis, which included 104 radiation therapy oncology ...

Joint supplement speeds melanoma cell growth

March 15, 2018
Chondroitin sulfate, a dietary supplement taken to strengthen joints, can speed the growth of a type of melanoma, according to experiments conducted in cell culture and mouse models.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.